Is INCYTE CORP (INCY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 18.8% / 30% | 5.4% / 30% | 2.05% / 5% | ✓ HALAL |
| DJIM | 0.2% / 33% | 18.8% / 33% | 5.4% / 33% | 2.05% / 5% | ✓ HALAL |
| MSCI | 0.6% / 33% | 51.5% / 33% | 14.7% / 33% | 2.05% / 5% | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 18.8% / 33% | 5.4% / 33% | 2.05% / 5% | ✓ HALAL |
| FTSE | 0.6% / 33% | 51.5% / 33% | 14.7% / 50% | 2.05% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 52.9% | |
| Operating Margin | 25.6% | |
| Net Margin | 25.0% | |
| Return on Equity (ROE) | 29.9% | |
| Return on Assets (ROA) | 13.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.4B |
| Free Cash Flow | $1.3B |
| Total Debt | $40M |
| Debt-to-Equity | 1.1 |
| Current Ratio | 3.3 |
| Total Assets | $7.0B |
Price & Trading
| Last Close | $92.26 |
| 50-Day MA | $99.07 |
| 200-Day MA | $90.24 |
| Avg Volume | 1.9M |
| Beta | 0.8 |
|
52-Week Range
$53.56
| |
About INCYTE CORP (INCY)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Purification Calculator
As a halal stock with 2.05% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is INCYTE CORP (INCY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), INCYTE CORP is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is INCYTE CORP's debt ratio?
INCYTE CORP's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.
Does INCYTE CORP require dividend purification?
Yes, INCYTE CORP has an impermissible income ratio of 2.05%, which means 2.05% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are INCYTE CORP's key financial metrics?
INCYTE CORP has a market capitalization of $18.0B, trailing P/E ratio of 14.1, and revenue of $5.1B. The company maintains a gross margin of 52.9% and a net margin of 25.0%. Return on equity stands at 29.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.